AnaptysBio (ANAB) Akcie Kurz
AnaptysBio Kurz
Tržby rostly o 36,8 % ročně za posledních 12 let na 234,60 Mil. USD. čistá marže společnosti AnaptysBio je nyní -5,6 %, nahoru z -91,5 % před několika lety. Medián cílové ceny analytiků je 75,50 USD, tedy nad aktuální cenu o 66,2 %. Z 17 analytiků jich 16 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie AnaptysBio
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model AnaptysBio a analýza akcií
Nejčastější otázky týkající se akcie AnaptysBio
The business model of AnaptysBio Inc is focused on discovering and developing novel antibody-based therapeutics for inflammation and immuno-oncology. With a strong emphasis on research and development, AnaptysBio utilizes its proprietary technology platform to generate highly specific therapeutic antibodies. These antibodies are aimed at targeting and modulating key immune system pathways to address various diseases, including inflammatory disorders, severe allergies, and certain types of cancers. By leveraging its expertise in antibody engineering and design, AnaptysBio aims to deliver innovative treatments that can improve patient outcomes and provide value to healthcare providers.
AnaptysBio Inc is primarily active in the biotechnology industry.
The main competitors of AnaptysBio Inc in the market are Regeneron Pharmaceuticals, Inc., Amgen Inc., and Novartis AG.
AnaptysBio Inc is a biotechnology company based in San Diego, California. Established in 2005, the company specializes in the discovery and development of therapeutic antibodies to address unmet medical needs. With a focus on inflammation, immuno-oncology, and rare diseases, AnaptysBio Inc utilizes its proprietary antibody discovery platform to identify and develop potential treatments. The company has forged collaborations with leading pharmaceutical companies and has a diverse pipeline of antibody candidates. AnaptysBio Inc's commitment to innovation and expertise in antibody-based therapies has positioned them as a prominent player in the biotech industry.
AnaptysBio Inc has achieved several significant milestones. The company has successfully developed novel antibody therapeutics for various severe diseases, including atopic dermatitis and peanut allergies. Additionally, AnaptysBio Inc has also entered into strategic collaborations with renowned pharmaceutical companies to further advance its drug pipeline. The company's dedication to research and development has led to the successful completion of multiple clinical trials, demonstrating their commitment to improving patient outcomes. With their innovative approach and strong partnerships, AnaptysBio Inc continues to pave the way in the field of biotechnology.
AnaptysBio Inc is primarily present in the United States.
AnaptysBio Inc represents a commitment to scientific innovation and excellence in the field of biotechnology. Its core values include a focus on discovering and developing novel antibody therapeutics to address unmet medical needs. The company strives to create value for patients, healthcare professionals, and shareholders through its cutting-edge research and development efforts. With a corporate philosophy centered around collaboration, AnaptysBio Inc aims to leverage its expertise and partnerships to drive forward breakthrough therapies that have the potential to improve patients' lives and revolutionize healthcare.
Analytici aktuálně stanovují průměrnou cílovou cenu 73,67 USD pro akcii AnaptysBio (medián: 75,50 USD), tedy +52,6 % vůči poslední ceně. Konsensus vychází z 17 hodnocení analytiků.
17 analytiků aktuálně hodnotí akcii AnaptysBio: 16 doporučuje koupit, 1 držet a 0 prodat. Pro rok 2026 analytici očekávají u AnaptysBio tržby 115,66 Mil. USD a zisk na akcii 4,65 USD.
Při aktuálním kurzu se akcie AnaptysBio obchoduje za 40,47 EUR (45,43 USD).
Akcie AnaptysBio (ANAB) je kótována na 5 burzách, mimo jiné: NASDAQ (ANAB), London (0HFQ.L), Frankfurt (AN6.F), München (AN6.MU), Düsseldorf (AN6.DU).
AnaptysBio Inc is an innovative biotechnology company that focuses on the discovery and development of new biological therapeutics. The company was founded in 2005 in San Diego, California, and has since gained a leading position in the industry. The business model of AnaptysBio is based on the development of highly effective antibodies with a focus on inflammatory diseases and cancer. The scientists and developers at AnaptysBio use the latest technologies to identify and develop potential candidates in a rapid, precise, and cost-effective approach. AnaptysBio takes a differentiated approach to antibody identification and specializes in the development of biological therapeutics. AnaptysBio has a wide range of products, including Atrmab, ANB020, ANB019, and Etokimab. Atrmab is a nasal administration antibody product developed to treat allergic diseases such as hay fever. ANB020 is an antibody specifically targeting the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. On the other hand, the antibody ANB019 is being developed as a therapy option for both Generalized Pustular Psoriasis (GPP) and Palmoplantar Pustular Psoriasis (PPP). Etokimab, on the other hand, aims to treat tessin and chronic pruritus. This is a non-specific skin disease characterized by constant itching and tingling. By developing innovative therapies, AnaptysBio is able to achieve significant advancements in the field of biological medicines. These therapeutics will help improve the lives of patients in various stages of the disease. AnaptysBio benefits from serving a small but rapidly growing niche in the industry. There is a high demand for specialized biological medicines, as these medicines are often more effective and better tolerated than traditional medicines and are therefore preferred by many doctors. AnaptysBio finances its business activities through investment capital and strategic partnerships with large pharmaceutical companies. In the early stages of biological therapeutic development, AnaptysBio plays an important role by conducting proof-of-concept studies and demonstrating the potential of new therapeutics. Once the therapeutics move into clinical phases, pharmaceutical companies seek collaborations to conduct joint clinical trials and enter the market. Overall, AnaptysBio is a successful biotech company that is capable of revolutionizing therapy approaches for inflammatory and cancerous diseases. Through collaboration with large pharmaceutical companies and the development of innovative products, AnaptysBio is in a strong position to achieve further growth and success.
Tržby očekávané za AnaptysBio činí 115,66 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za AnaptysBio činí 145,89 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) AnaptysBio je aktuálně 9,76. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie AnaptysBio.
Poměr ceny k tržbám (P/S) AnaptysBio je aktuálně 12,31. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie AnaptysBio.
Score kvality pro AnaptysBio je 6/10.
ISIN AnaptysBio je US0327241065. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN AnaptysBio je A2AJ8C. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker AnaptysBio je ANAB. Symbol tickeru se používá k obchodování akcií AnaptysBio na burze.
AnaptysBio akcie
AnaptysBio Peer Group
AnaptysBio Ticker
AnaptysBio FIGI
Všechny fundamentální údaje o AnaptysBio v podrobné analýze
Naše analýzy akcií společnosti AnaptysBio zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti AnaptysBio. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: